You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • S109 Targeting the prostacyclin pathway in the treatment of connective tissue disease associated pulmonary arterial hypertension (PAH): insights from the randomised controlled griphon trial with selexipag

Article metrics

Article menu
Download PDFPDF
Declarations of Interest
S109 Targeting the prostacyclin pathway in the treatment of connective tissue disease associated pulmonary arterial hypertension (PAH): insights from the randomised controlled griphon trial with selexipag

 

Online download statistics by month:

Online download statistics by month: November 2016 to August 2024

AbstractFullPdf
Nov 20164302
Dec 20164803
Jan 20171000
Feb 2017602
Mar 2017300
Apr 2017600
May 20171202
Jun 20171001
Jul 2017400
Aug 20171800
Sep 20172801
Oct 20171400
Nov 20171001
Dec 20171200
Jan 20181400
Feb 20181600
Mar 2018400
Apr 20183400
May 20181400
Jun 20181401
Jul 20181600
Aug 20181800
Sep 20181000
Oct 20181402
Nov 2018800
Dec 20181001
Jan 2019900
Feb 2019300
Mar 20191403
Apr 2019100
May 2019400
Jun 2019700
Jul 2019200
Aug 2019300
Sep 2019400
Oct 2019502
Nov 20191006
Dec 2019404
Jan 2020202
Feb 2020403
Mar 2020402
Apr 2020001
May 2020403
Jun 2020502
Jul 20201803
Sep 20202004
Oct 2020400
Nov 2020603
Dec 2020002
Jan 2021600
Feb 2021004
Mar 2021201
Apr 2021404
Jun 2021006
Jul 2021002
Aug 2021003
Sep 2021002
Oct 202110016
Nov 20210010
Dec 2021600
Jan 2022401
Feb 2022200
Mar 20221000
Apr 2022202
May 2022607
Jun 2022202
Jul 2022201
Aug 2022201
Sep 2022807
Oct 2022203
Nov 2022400
Dec 2022601
Jan 2023202
Feb 2023200
Mar 20231000
Apr 2023001
May 2023402
Jul 2023202
Aug 2023601
Sep 2023602
Oct 2023201
Nov 2023603
Dec 20231200
Jan 2024200
Feb 2024601
Mar 2024800
Apr 20241005
May 2024400
Jun 2024600
Jul 2024200
Aug 2024800
Total7050149